Coronavirus (COVID-19) News
Filter News
Found 2,541 articles
-
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
2/15/2023
Shionogi & Co., Ltd. announced progress on its comprehensive clinical development program for the novel COVID-19 oral antiviral ensitrelvir.
-
The COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners.
-
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
2/14/2023
Clover Biopharmaceuticals, Ltd. announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose campaign targeting older adults, immunocompromised individuals and individuals with comorbidities.
-
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
2/8/2023
PDS Biotechnology Corporation announced that preclinical studies involving Infectimune™, PDS Biotech’s novel investigational immune activating platform, were published in the peer-reviewed journal, Viruses, demonstrating the technology’s ability to generate a broad immune response against viruses, including SARS-CoV-2 and multiple strains of influenza.
-
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19
2/2/2023
Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, released the final results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.
-
Axcella Therapeutics' Long COVID fatigue therapeutic is moving forward as the company received guidance from the MHRA and filed an IND with the FDA seeking a Phase IIb/III trial.
-
Therma Bright Inc. Invests in Ischemic Stroke Blood Clot Retriever Technology Company Inretio Inc. based in Israel
1/19/2023
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd.
-
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
1/18/2023
Immuron Limited is pleased to provide shareholders and the market with a progress update on the US Department of Defense Uniformed Services University Clinical Evaluation of Travelan.
-
Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19
1/16/2023
Ascletis Pharma Inc. announces dosing of 4 healthy subjects of the first cohort in multiple-dose escalation Phase I clinical trial of oral 3-chymotrypsin like protease inhibitor ASC11 in combination with 100 mg ritonavir tablets for COVID-19.
-
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
1/16/2023
Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, provided updates on the commercialization of SCB-2019 in China and strategic priorities in 2023.
-
Meet Gilead’s COVID-19 Virus Variants Hunters
1/12/2023
Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called "variant hunters."
-
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
1/9/2023
Revive Therapeutics Ltd. announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto, which evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.
-
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
1/5/2023
The study conducted in 399 participants met its primary efficacy endpoint with a reduction of 72% of COVID-19 infection in the group treated with daily oral administration of ivermectin compared to the placebo group.
-
Lucira Health Submits EUA for Over-The-Counter (OTC) Use of its COVID-19 & Flu Test
1/3/2023
Lucira Health, Inc., a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.
-
Spear Bio expands NAB-Sure™ Assays to Support Study of SARS-CoV-2 Variants
1/3/2023
Spear Bio is expanding its NAB-Sure™ Neutralizing Antibody Test Kit product line with current SARS-CoV-2 variants.
-
CGTN: China monitors coronavirus mutations to adjust COVID-19 response
1/1/2023
With China loosening its COVID-19 restrictions, some experts have expressed concern that China's relaxation of COVID-19 limitations will enhance the likelihood of the virus mutating.
-
Government of Canada announces a temporary negative COVID-19 test requirement for travellers arriving from the People's Republic of China, Hong Kong or Macao
12/31/2022
As the COVID-19 pandemic has continued to evolve, the Government of Canada has taken a prudent and measured approach to adjusting border measures to protect the health and safety of Canadians.
-
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
12/30/2022
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination and influenza stand-alone vaccine candidates.
-
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
12/30/2022
ValnevaSE, a specialty vaccine company, reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.
-
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
12/27/2022
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19.